Patent details

EP2340837 Title: COMBINATION TREATMENT OF CANCER COMPRISING EGFR/HER2 INHIBITORS

Basic Information

Publication number:
EP2340837
PCT Application Number:
Type:
European Patent Granted for LU
Legal Status:
Lapsed
Application number:
EP111555827
PCT Publication Number:
First applicant's nationality:
Translation Language:
EPO Publication Language:
English
English Title of Invention:
COMBINATION TREATMENT OF CANCER COMPRISING EGFR/HER2 INHIBITORS
French Title of Invention:
TRAITEMENT COMBINÉ DU CANCER COMPRENANT DES INHIBITEURS EGFR/HER2
German Title of Invention:
KOMBINATIONSBEHANDLUNG GEGEN KREBS MIT EGFR/HER2-HEMMERN
SPC Number:

Dates

Filing date:
09/11/2006
Grant date:
15/03/2017
EP Publication Date:
06/07/2011
PCT Publication Date:
Claims Translation Received Date:
Translations Received Date (B1 EP Publication):
Translations Received Date (B2 EP Publication):
Translations Received Date (B3 EP Publication):
Publication date:
15/03/2017
EP B1 Publication Date:
15/03/2017
EP B2 Publication Date:
EP B3 Publication Date:
Lapsed date:
09/11/2017
Expiration date:
09/11/2026
Renunciation date:
Revocation date:
Annulment date:

Owner

From:
15/03/2017
 
 

Name:
Boehringer Ingelheim International GmbH
Address:
Binger Strasse 173, 55216 Ingelheim am Rhein, Germany (DE)

Inventor

1

Name:
Stehle, Gerd
Address:
Germany (DE)

2

Name:
Baum, Anke
Address:
Austria (AT)

3

Name:
Solca, Flavio
Address:
Austria (AT)

4

Name:
Amelsberg, Andree
Address:
United States (US)

5

Name:
Van Meel, Jacobus C.A.
Address:
Austria (AT)

Priority

Priority Number:
05110669
Priority Date:
11/11/2005
Priority Country:
European Patent Office (EPO) (EP)

Classification

IPC classification:
A61K 31/337; A61P 35/00;

Publication

European Patent Bulletin

Issue number:
201711
Publication date:
15/03/2017
Description:
Grant (B1)

Annual Fees

Annual Fee Due Date:
Annual Fee Number:
Expected Payer:
Last Annual Fee Payment Date:
Last Annual Fee Paid Number:
Payer:
Filing date Document type Number of pages
30/03/2018 Outgoing Correspondence 1